Amplitude Ventures logo

Amplitude Ventures

Crunchbase
Pitchbook
Crunchbase

Deals on record

6

Common Fundraising Type

Series B

Fluid Biomed logo
Fluid Biomed

Medical device

Amplitude Ventures logo
ShangBay Capital logo
METIS Innovative logo
LifeArc Ventures logo
IAG Capital Partners logo

Fluid Biomed Inc. is a medical device company developing the world's first bioabsorbable polymer-based stent for treating brain aneurysms.

Series A
$27M
12/16/2024
Article
Evommune logo
Evommune

Biotechnology

RA Capital Management logo
Verition Fund Management logo
Symbiosis logo
RTW Investments logo
Sectoral Asset Management logo
Pivotal bioVenture Partners logo
NEXTBio Capital logo
Marshall Wace logo

Evommune, Inc. is a biotechnology company focused on developing treatments for chronic inflammatory diseases.

Series C
$115M
10/31/2024
Article
Nomic logo
Nomic

Protein profiling

SR One logo
Real Ventures logo
Lux Capital logo
AVANT BIO logo
Amplitude Ventures logo

Nomic Bio specializes in advanced protein profiling to extend health spans through its nELISA™ platform.

Series B
$42M
09/17/2024
Article
Radiant Bio logo
Radiant Bio

Multabody™ platform

Amplitude Ventures logo
Toronto Innovation Acceleration Partners logo
FACIT logo
Bill & Melinda Gates Foundation logo
BDC Capital logo
abrdn logo
Alexandria Venture Investments logo

Radiant Biotherapeutics develops innovative therapies using its proprietary Multabody™ platform to target oncology, inflammation, immunology, and infectious diseases.

Series A
$35M
09/11/2024
Article
Ability Biologics logo
Ability Biologics

Antibody Therapeutics

Amplitude Ventures logo
Fonds de solidarit FTQ logo
Page One Ventures logo
Charles River Laboratories logo
Alexandria Venture Investments logo

Ability Biologics is a biotech startup focused on creating next-generation antibody therapeutics for unmet medical needs using their proprietary AI platform, AbiLeap™.

Seed
$12M
12/06/2023
Article

Tentarix Biotherapeutics is a biotechnology company that uses its proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics.

Series B
$35M
09/06/2023
Article